Sort   by:  
 Page size 
UnknownSafety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Not available
S-EPMC5559878 | biostudies-literature
UnknownVery large database of lipids: rationale and design.
Not available
S-EPMC6649455 | biostudies-literature
UnknownDesign innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
Not available
S-EPMC3481179 | biostudies-literature
UnknownT<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.
Not available
S-EPMC12644732 | biostudies-literature
UnknownGenomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Not available
S-EPMC8252519 | biostudies-literature
UnknownAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Not available
S-EPMC5538020 | biostudies-literature
UnknownAnti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Not available
S-EPMC10540058 | biostudies-literature
UnknownMEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
Not available
S-EPMC9629420 | biostudies-literature
UnknownRisk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia.
Not available
S-EPMC10169428 | biostudies-literature
UnknownGenetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Not available
S-EPMC10317892 | biostudies-literature
Sort   by:  
 Page size